You nominated and our expert judging panels deliberated – and now, we proudly showcase this diversity of talent in The Pathologist’s 2020 Power List.
Kidney discard rates are higher than ever – but the procurement biopsies that often rule out their use are unreliable and need to be standardized
Higher tumor mutational burden is linked to improved survival across multiple cancer types.
Simultaneous multiplex immunohistochemistry can provide efficient testing of multiple targets when diagnosing and selecting treatment for cancer
A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.
David L. Rimm
David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.
Techniques like droplet digital PCR technology can assist with early monitoring of cancer immunotherapy to ensure the right treatment for each patient
Genomic research has a diversity problem that could restrict the future effectiveness of precision medicine for minority groups
Prostate cancer prognosis presents a challenge – but a new algorithmic tool may help personalize predictions
Decentralized genomic testing in China will allow earlier breast cancer diagnosis and more personalized treatment decisions
New guidelines for CYPC29 genotyping ensure that the correct alleles are tested and patients are prescribed the correct doses of common drugs
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.